Direct compression of a 500 mg immediate-release paracetamol tablet using PVP VA64-grade copovidone (vinylpyrrolidone-vinyl acetate copolymer 60:40) and microcrystalline cellulose 102 proceeds through a sequence in which dry copovidone functions as an intragranular binder at 2.5–4.0% w/w. The blend is prepared by passing paracetamol, lactose monohydrate, microcrystalline cellulose 102, croscarmellose sodium 3.0% w/w, and copovidone through a 0.8 mm mesh screen, followed by blending in a V-blender at 25 rpm for 15 min. Magnesium stearate 0.5% w/w is then added and blended for 3 min. The powder is compressed on a rotary tablet press with precompression 8–12 kN and main compression 18–25 kN; target hardness is 80–120 N and friability is maintained below 0.5% after 100 revolutions according to USP <1216>. The lower equilibrium moisture uptake of copovidone relative to povidone K30 reduces the risk of punch filming at processing relative humidity up to 60%, but at ambient relative humidity above 65% the blend should be pre-dried at 40–45 °C for 1–2 h before compression. The finished tablet is evaluated for disintegration and dissolution using USP <701> and USP <711>. Published direct-compression data for this specific paracetamol-copovidone configuration are limited, so compression force and friability targets are established on the production press rather than transferred from small-scale model blends.

What Limits Aqueous Binder Solution Viscosity in a High-Shear Granulation Train?

High-shear wet granulation with copovidone as a binder typically uses an aqueous solution at 8.0–12.0% w/w; the viscosity of these solutions remains in the range 4–8 mPa·s at 20 °C. The upper concentration is limited by loss of spray pattern integrity through a 1.0 mm two-fluid nozzle: above 10 mPa·s, the spray forms droplets larger than 200 µm, producing overwetted pockets and heterogeneous granule growth. In a 25 kg batch, the solution is metered at 0.5–1.5 L/min into a high-shear mixer operating at impeller tip speed 4–6 m/s and chopper speed 1500–3000 rpm. Torque is used as the endpoint control; termination is typically set at 3–5 N·m or power draw of 4–7 A. The wet mass is passed through a 1.2 mm sieve and dried in a fluid-bed dryer with inlet air at 65–70 °C and exhaust air at 35–40 °C to a loss on drying of 1.5–2.5%. If ethanol is added at 20–30% w/w to reduce binder solution surface tension, the drying step must demonstrate residual ethanol below the ICH Q3C Class 3 limit of 5000 ppm. The dried granule D50 is maintained between 150 µm and 250 µm by dry milling through a cone mill at 2500 rpm. Tablet formulations from this route typically contain drug 70–75% w/w, copovidone 2.0–5.0% w/w, crospovidone or croscarmellose sodium 3.0–5.0% w/w, and filler to 100% w/w. Compression is performed after lubrication with magnesium stearate 0.5–1.0% w/w; tablet friability is checked per USP <1216> and content uniformity per USP <905>.

Capsule filling of a 300 mg cefalexin monohydrate formulation places stricter flow and density constraints on the copovidone-bound granulate than tablet compression does. The granulate is produced with an aqueous copovidone solution at 5.0% w/w sprayed to achieve 3.0% w/w dry polymer; the wet mass is passed through a 1.0 mm screen and dried in a fluid-bed dryer to LOD 1.0–1.8%. After drying, the granules are milled through a 0.8 mm cone mill at 2500 rpm; the resulting particle-size profile is typically D10 60–90 µm, D50 150–200 µm, and D90 400–600 µm. Bulk density is adjusted to 0.55–0.65 g/mL and tapped density to 0.70–0.80 g/mL, giving a Carr index of 15–20 and Hausner ratio of 1.15–1.25 when measured by USP <616>. The granules are filled on a dosator-type capsule machine with pin settings of 5–7 mm and 2–3 tamping stations at speeds up to 200,000 capsules/h; fill weight is monitored gravimetrically every 15 min and individual capsule weight variation is released against USP <905>. Copovidone reduces granule friability during pneumatic transfer, but if the granules are overdried below 1.0% LOD, electrostatic charging increases and fill weight variability rises above ±5%. Empty hard-gelatin or hypromellose capsules are used; dissolution testing is performed in 900 mL of 0.1 N HCl at 37 °C using USP apparatus II at 50 rpm with a Q value of 80% at 30 min where the drug substance is highly soluble in acidic media.

Amorphous Solid Dispersion Extrusion Window and Kinetic Boundaries

Hot-melt extrusion of a BCS Class II compound with copovidone as the amorphous solid dispersion carrier is performed on a twin-screw extruder with L/D 40:1–48:1 and zone temperatures between 120 °C and 170 °C. The polymer:drug ratio is generally 70:30–90:10 w/w; a single glass transition temperature after extrusion is used as the primary miscibility indicator, with the observed value dependent on drug load and hydrogen-bonding capacity. The preblend must be dried to residual water below 0.5% by vacuum drying at 40–50 °C for 6–8 h. Feeding is controlled at 1.0–3.0 kg/h with screw speed 150–300 rpm; specific energy input is typically 0.3–0.8 kWh/kg, while melt pressure is maintained at 20–50 bar and torque at 5–8 N·m. Vacuum degassing is applied at the vent port at -0.6 to -0.8 bar to remove residual water and dissolved gases. Above 180 °C, the vinyl acetate fraction of copovidone can undergo ester hydrolysis and discoloration; below 120 °C, high-torque excursions above 10 N·m become frequent for high-melting APIs. After extrudate air cooling, the strand is pelletized and milled; 1.0–2.0% w/w colloidal silicon dioxide may be added to the milled extrudate to control static charge and flow. Dissolution evaluation uses USP apparatus II in 900 mL of pH 6.8 phosphate buffer at 75 rpm, with sink conditions adjusted for the API; published supersaturation data for copovidone solid dispersions are API-specific, so a universal dissolution target is not applicable. Stability protocols follow ICH Q1A stress conditions and physical stability is assessed by XRPD or DSC to confirm absence of recrystallization over the assigned shelf life.

Low-viscosity copovidone is evaluated in an oral suspension of a poorly water-soluble active at 5.0% w/v drug load, where its function is not primary suspension viscosity but crystal-habit stabilization. The polymer is dissolved in purified water at 0.5–2.0% w/v, and the active is dispersed by high-shear homogenization at 2000 rpm for 30 min in the presence of xanthan gum 0.2–0.4% w/v as the structuring agent. The pH is adjusted to 4.5–6.5 with citrate buffer, and preservative is added at 0.1–0.2% w/v. Copovidone adsorbs onto the drug crystal surface and slows diffusion-controlled growth during temperature cycling between 5 °C and 40 °C; this effect is monitored by particle-size analysis and microscopy rather than assumed from molecular weight alone. The formulation is filled into amber polyethylene terephthalate bottles and stored at 25 °C / 60% RH; viscosity remains low enough to allow a dosing syringe with a 2.0 mm orifice. Copovidone is not a surfactant of the polysorbate type and cannot replace a micellar solubilizer; if the drug requires micellar solubilization, a separate surfactant system must be used. The polymer is incompatible with strong oxidizing preservatives such as sodium metabisulfite, and aqueous solutions should be protected from light to avoid free-radical chain reactions. Published data for this specific oral suspension configuration are limited, so the suspension design space is established by screening studies under the same thermal cycling conditions intended for the shelf-life specification.

When Copovidone Is Selected for Injectable or Sterile-Route Use, Which Compendial Gaps Govern?

Injectable use of copovidone is not harmonized across the major pharmacopoeias; published regulatory precedence is strongest for oral tablets, capsules, and granules, while parenteral-grade qualification must be generated by the sponsor. If the polymer is required at 0.1–1.0% w/v as a crystallization inhibitor in a sterile suspension or solution, the supplier must demonstrate control of bacterial endotoxins below a level justified by the maximum intended dose and body weight, using USP <85>; particulate matter in the finished injection must meet USP <788> for subvisible particles and USP <790> for visible particles. Elemental impurities are assessed by ICH Q3D, but no harmonized monograph limits exist for copovidone-specific residual peroxides; the sponsor must establish an in-house limit from batch history and route-specific risk assessment. Autoclaving aqueous copovidone solutions at 121 °C for 15 min may hydrolyse the vinyl acetate residues and shift the monomer ratio, so terminal filtration through a 0.22 µm PVDF or PES membrane is preferred where the product is heat-sensitive. The acetate hydrolysis rate increases outside pH 5.0–7.0; therefore buffering within this range is advisable if the solution is held for more than 24 h before filling. Because the polymer is not a primary surfactant, the formulation must include a compendial wetting agent if the active is poorly wetted. No published population pharmacokinetic or safety data specific to injectable copovidone are available, so the injectable use should be restricted to scenarios where the physicochemical benefit is demonstrated and the route-specific regulatory authority has accepted the qualification file.

Copovidone is applied as a tablet subcoat before enteric coating when the final dosage form is a delayed-release or gastro-resistant tablet. The subcoat solution contains 5.0–10.0% w/w copovidone in purified water, with polyethylene glycol 400 at 10–20% w/w of polymer as plasticizer and talc at 5–10% w/w of polymer as anti-tack agent. In a side-vented pan coater handling a 25–100 kg tablet bed, inlet air is set at 60–70 °C and exhaust at 40–50 °C; the tablet bed temperature is maintained at 38–45 °C to prevent over-wetting. Spray rate is 8–15 g/min/kg of tablet bed, atomizing air pressure is 1.0–2.0 bar, and pan speed is 2–8 rpm. The subcoat weight gain is typically 1.0–2.0%, while a cosmetic copovidone coat may require 2.0–4.0%. Twinning and picking occur when the spray rate exceeds the drying capacity or when the atomizing pressure falls below 1.0 bar, creating large droplets. The coat uniformity is evaluated by visual inspection, weight-gain determination, and disintegration testing per USP <701>; dissolution after enteric coating is verified using USP <711> in appropriate acidic and buffer stages. Published data for this specific copovidone subcoat configuration are available from coating vendors, but scaling from laboratory to production pan requires re-optimization because tablet surface temperature and spray flux are not directly scalable across pan sizes.